Sarepta Rises as Drug Betters Conditions of Rare Muscle Disease

  • Patients on eteplirsen able to walk farther than benchmark
  • Data aids Sarepta in battle with BioMarin to treat DMD

Sarepta Therapeutics Inc. rose the most in more than four months after its mid-stage trial showed improved walking capability and increased muscle protein for patients with a rare and deadly muscle-wasting disease.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.